

26979-0002 US

TRANSMIT LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C.

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

Not Yet Assigned

09/889687

INTERNATIONAL APPLICATION NO

PCT/AU00/00025

INTERNATIONAL FILING DATE

January 18, 2000

PRIORITY DATE CLAIMED

January 18, 1999

TITLE OF INVENTION

PROTECTING GROUPS FOR CARBOHYDRATE SYNTHESIS

APPLICANT(S) FOR DO/EO/US

DEKANY, Gyula, PAPAGEORGIOU, John, BORNAGHI, Laurent &amp; Francois

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☒ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

## Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☐ Other items or information:

U.S. APPLICATION NO. (if known, see 37 CFR 1.53)  
Not Yet Known **09/889687**

INTERNATIONAL APPLICATION NO PCT/AU00/00025

ATTORNEY'S DOCKET NUMBER  
26979-0002 US21. ☒ The following fees are submitted:

CALCULATIONS PTO USE ONLY

**BASIC NATIONAL FEE (37 CFR 1.492(a)(1) - (5)):**

Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and international Search Report not prepared by the EPO or JPO..... **\$1000.00**

International preliminary examination fee (37 CFR 1.482) not paid to  
USPTO but International Search Report prepared by the EPO or JPO..... **\$860.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO  
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... **\$710.00**

International preliminary examination fee (37 CFR 1.482) paid to USPTO  
but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... **\$690.00**

International preliminary examination fee (37 CFR 1.482) paid to USPTO  
and all claims satisfied provisions of PCT Article 33(1)-(4)..... **\$100.00**

**ENTER APPROPRIATE BASIC FEE AMOUNT**

=

\$1,000

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	11 - 20 =	0	x <b>\$18.00</b>	\$
Independent claims	1 - 3 =	0	x <b>\$80.00</b>	\$

MULTIPLE DEPENDENT CLAIM(S) (if applicable) + **\$270.00**

\$

**TOTAL OF ABOVE CALCULATIONS =**

\$500

☒ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are  
reduced by 1/2.

\$500

**SUBTOTAL =**

\$500

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

**TOTAL NATIONAL FEE =**

\$

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR) 3.28, 3.31)). **\$40.00** per property +

\$

**TOTAL FEES ENCLOSED =**

\$500

Amount to be  
refunded:

\$

charged:

\$

a. ☒ a check in the amount of \$ 500 to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. 08-1641 in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment  
to Deposit Account No. 08-1641. A duplicate copy of this sheet is enclosed.d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public **Credit card information  
should not be included on this form.** Provide credit card information and authorization on PTO-2038.**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or  
(b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO

William Schmonsees

Heller Ehrman White &amp; McAuliffe LLP

275 Middlefield Road

Menlo Park, CA 94025-3506

Main: (650) 324-7000

Fax: (650) 324-0638

Date: July 18, 2001

SIGNATURE

NAME: William Schmonsees

REGISTRATION NUMBER: 31,794

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of	)	Examiner: Not Assigned
DEKANY <i>et al.</i>	)	Group Art Unit: Not Assigned
Serial No: Not Yet Assigned	)	Customer No.: 25213
Filed: July 18, 2001	)	
For: <b>PROTECTING GROUPS FOR</b>	)	
<b>CARBOHYDRATE SYNTHESIS</b>	)	<b><u>PRELIMINARY AMENDMENT</u></b>
Docket No.: 26979-0002 US	)	

Express Mail Label No.: EL912433811US

Mailed in Palo Alto, CA on: July 18, 2001

BOX PATENT APPLICATION  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Please preliminarily amend the above application as indicated below.


**IN THE CLAIMS**

Please cancel claims 1-11.


Please add new claims 12-22.

**CLAIMS**

12. A universal monosaccharide building block of General Formula I or  
General Formula II



I



II

in which,

A is a leaving group selected from the group consisting of -SR; where R is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, halogen; trichloroacetimidoyl; sulphoxide; and -O- alkenyl;

$X_1$ ,  $X_2$ , and  $X_3$  are independently selected from H, O, N, or  $N_3$ , with the proviso that only one of  $X_1$ ,  $X_2$ , and  $X_3$  may be H, N or  $N_3$  in any molecule;


$X_4$  is H,  $-CH_2O$ ,  $-CH_2N$ ,  $-CH_3$ ,  $-CH_2N_3$  or  $-COO-$ , with the proviso that  $X_4$  may only be H,  $-CH_2N$ ,  $-CH_3$  or  $CH_2N_3$  when none of  $X_1$  to  $X_3$  is H; and

B, C, D and E are different, and are selected from protecting groups which can be cleaved orthogonally in any order,

and in which,

B or C or D or E is absent if the corresponding  $X_1$  to  $X_3$  is H or  $N_3$ , or if the corresponding  $X_4$  is H,  $-CH_3$  or  $-CH_2N_3$ .

13. A monosaccharide building block according to claim 12, which is a compound of General Formula III




III

in which,

A, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are as defined for General Formulae I and II, and

B<sub>1</sub>, C<sub>1</sub>, D<sub>1</sub>, and E<sub>1</sub> are orthogonal carbohydrate protecting groups selected from protecting group sets 1, 2, 6 and 8 as herein defined.

14. A monosaccharide building block according to claim 12, which is a compound of General Formula IV




IV

in which,

A, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are as defined for General Formulae I and II, and

B<sub>2</sub>, C<sub>2</sub>, D<sub>2</sub> and E<sub>2</sub> are selected from the members of protecting group set 1, and in themselves constitute an orthogonal set.

15. A monosaccharide building block according to claim 14, in which the members of protecting group set 1 are levanoyl, chloroacetate, *p*-methoxybenzyloxycarbonyl and 2-trimethylsilylethylcarbonate.
16. A monosaccharide building block according to claim 12, which is a compound of General Formula V



V

in which,

A, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are as defined for General Formulae I and II, and

B<sub>3</sub>, C<sub>3</sub>, D<sub>3</sub> and E<sub>3</sub> are an orthogonal set of protecting groups selected from amongst the members of set 1 and from the remaining orthogonal sets.

17. A method of synthesis of a molecule selected from the group consisting of glycoconjugates of non-carbohydrate molecules, neo-glycoconjugates and oligosaccharides, comprising the step of using a monosaccharide building block according to claim 12.
18. A method according to claim 17, in which the molecule comprises one or more compounds in which substituents are linked to a pyranose or furanose ring.
19. A method according to claim 17, in which the molecule comprises a sugar analogue.

20. A method according to claim 18, in which the molecule comprises a sugar analogue.

21. A method according to claim 17, in which the synthesis is carried out in solution.


22. A method according to claim 17, in which the synthesis is carried out on a solid-phase support.

### IN THE SPECIFICATION


Please add the following paragraph before the paragraph at page 2, line 24:

--Orthogonal protecting strategies and conditions are reviewed in the textbook, "Protecting Groups in Organic Synthesis", by Green and Wicks (3rd edition).

Please replace the figures I and II on page 4 with the following amended figures I and II:



I



II

Please replace the lines 27-31, page 4 with the following rewritten lines:

--X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub> are independently selected from H, O, N, or N<sub>3</sub>, with the proviso that only one of X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub> may be H, N, or N<sub>3</sub> in any molecule;


--X<sub>4</sub> is H, -CH<sub>2</sub>O, -CH<sub>2</sub>N, -CH<sub>3</sub>, -CH<sub>2</sub>N<sub>3</sub> or -COO-, with the proviso that X<sub>4</sub> may only be H, -CH<sub>2</sub>N, -CH<sub>3</sub> or -CH<sub>2</sub>N<sub>3</sub> when none of X<sub>1</sub> to X<sub>3</sub> is H; and

Please replace the paragraph beginning at page 5, line 1 with the following rewritten lines:

--B, C, D, and E are different, and are selected from protecting groups which can be cleaved orthogonally in any an order, and in which

--B or C or D or E is absent if the corresponding X<sub>1</sub> to X<sub>3</sub> is H or N<sub>3</sub>, or if the corresponding X<sub>4</sub> is H, -CH<sub>3</sub> or -CH<sub>2</sub>N<sub>3</sub>.

Please replace the figure III on page 7 with the following amended figure III:




III

Please replace the lines 2-3, page 8 with the following line:

--A, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are as defined for General Formulae I and II, and

Please replace the figure IV on page 8 with the following amended figure IV:




IV

Please replace the lines 14-15, page 8 with the following line:

--A, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are as defined for General Formulae I and II, and

Please replace the figure V on page 8 with the following amended figure V:



V

Please replace the lines 2-3, page 9 with the following line:

--A, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are as defined for General Formulae I and II, and

Please replace line 16, page 24 with the following rewritten line:

-- glucopyranoside (24)

Please replace line 9, page 29 with the following rewritten line:

-- acetyl-1-thio- $\beta$ -D-galactopyranoside (31)

The applicant wishes to change the order in which the inventors are named to the following order:

DEKANY, Gyula  
PAPAGEORGIOU, John  
BORNAGHI, Laurent Francois

Applicant submits that the pending claims are directed to allowable subject matter, and respectfully requests consideration and allowance of the application. No new matter is added by the amendments, because the amended claims find support in the application as filed. Entry of the amendment and allowance of the claims are requested.

Respectfully submitted,

By: 

William Schmonsees  
Registration No. 31,794

Heller Ehrman White & McAuliffe LLP  
275 Middlefield Road  
Menlo Park, CA 94025  
**Direct Dial: (650) 324-7041**  
Facsimile: (650) 324-0638

310180 v03.SV (6nc403!.DOC)  
7/18/01 11:48 AM (26979.0002)

PROTECTING GROUPS FOR CARBOHYDRATE SYNTHESIS

This invention relates to methods of synthesis of glycoconjugates, and in particular to orthogonally protected carbohydrate building blocks. The invention provides collections of orthogonally protected monosaccharides as universal building blocks for the synthesis of glycoconjugates of non-carbohydrate molecules, neo-glycoconjugates and oligosaccharides. This orthogonal protection strategy allows for the specific deprotection of any substituent on the saccharide ring, and greatly facilitates targeted or library-focused carbohydrate related syntheses.

15 BACKGROUND OF THE INVENTION

Oligosaccharides are important components of a variety of different types of biological molecules, and are involved in antigenic recognition and cell-cell interactions. In many cases, bio-molecules require conjugation with a carbohydrate component in order to be fully functional. In order to enable investigation of the biological function, and to exploit the exquisite biochemical and antigenic specificity of oligosaccharides, it is essential to have access to highly defined, specific synthetic oligosaccharides. Therefore achieving efficient, cost-effective synthesis of oligosaccharides and glycoconjugates by either solution or solid phase methods is of the utmost importance.

This task is enormously complicated by the complexity of oligosaccharides. Because of the number of sites which can carry substituents, and the number of possible ways in which two saccharide molecules can be linked, the number of permutations is enormously high.

In naturally-occurring oligosaccharides D-glucose, D-galactose L-fucose, D-mannose, D-glucosamine and D-galactosamine are among the most common sugar residues. To construct oligosaccharides and carbohydrate conjugates

- 2 -

using these sugars, current methodologies require long, protracted syntheses, involving synthesis of as many as one hundred different specially-protected sugar donors in order to cover adequately all the possible permutations of glycosidic link formation (eg. 1-3, 1-4), link type (eg.  $\alpha$  or  $\beta$ ) and to include all possible branching points in the oligosaccharide.

Orthogonal protection of bi-functional molecules has been a widely used technique in organic chemistry, which provided general building blocks for selected syntheses. However, orthogonal protection in the case of molecules with a greater degree of functionalisation is quite rare. Our technology involves penta-functional monosaccharide building blocks, which require a much higher level of chemical specificity to attain the appropriate orthogonality.

Orthogonal protection has been defined by Merrifield as follows:

"The principle of orthogonal stability requires that only those protecting functions should be used that can be cleaved under different reaction conditions without affecting the other functions present" (Merrifield, 1977)

Although the use of orthogonal protection would greatly facilitate carbohydrate related synthesis, there has been limited success in devising suitable protecting groups and methods.

Wong et al. synthesised a universal building block with chloroacetyl, *p*-methoxybenzyl, levulinyl and *tert*-butyldiphenylsilyl protecting groups, selectively removable with sodium bicarbonate, trifluoroacetic acid, hydrazine and hydrogen fluoride-pyridine respectively, on a galactopyranose ring with an aryl-thio leaving group at the glycosidic position. This building block was used solely to synthesise a 6-hexanate glycoside. The subsequent recombinant oligosaccharide library formation focused on using the 6-hexanate derivatised building block which

- 3 -

exhibits only four degrees of orthogonality (Wong *et al.*, 1998).

Similarly Kunz and coworkers synthesised an orthogonally protected D-glucopyranose derivative, but  
5 synthetic manipulations were only performed on the aglycon. These authors describe orthogonal protection of hydroxyl groups on a monosaccharide linked at C1 via a thioglycoside group to a solid support or to a succinimide moiety. In  
10 this case the protecting groups are acetyl or methyl at C2, allyl at C3, ethoxyethyl at C4, and tert-butyldiphenylsilyl at C6. The thioglycoside anchor functionalized in the side-chain is stated to be crucial. Again there is no suggestion that this protection system can be used for substituted sugars. Kunz's orthogonally-protected building  
15 block was not used for glycosylation or construction of glycoconjugates or neo-glycoconjugates, by directly attaching functionalities to the pyranose ring (Wunberg *et al.* 1998).

In our earlier International Patent Applications  
20 No. PCT/AU97/00544, No. PCT/AU98/00131 and No. PCT/AU98/00808, we described protecting and linking groups which enabled oligosaccharides and aminooligosaccharides to be synthesised using solid phase methods of the type which for many years have been used in  
25 peptide synthesis. In addition the protecting groups, described therein were useful for solution-phase synthesis. The entire disclosures of these specifications are incorporated herein by this reference.


We have now devised new types of building blocks  
30 which greatly facilitate the synthesis of oligosaccharides and glycoconjugates, using orthogonally-protected saccharide building blocks with five degrees of orthogonality. These building blocks contain a leaving group or latent leaving group at the glycosidic position, and  
35 another four orthogonally-protected functional groups around the carbohydrate ring.

- 4 -

Using our approach with six universal building blocks based on six of the most common naturally occurring sugars, any one of the one hundred sugars referred to above may be quickly synthesised in a facile manner, using simple, well-known protecting group chemistry. The years of work and complex protection strategies required to produce these one hundred building blocks by previously-available methods can be avoided by use of our six universal building blocks, which do not require a high level of skill to use, and enable one to achieve the synthesis of a specific desired oligosaccharide or glycoconjugate much faster and more efficiently than previously possible.

#### SUMMARY OF THE INVENTION

In its most general aspect the invention provides a universal monosaccharide building block of General Formula I or General Formula II



in which

A is a leaving group, including but not limited to groups such as -SR; where R is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, halogen; trichloroacetimidoyl-; sulphoxide; -O-alkenyl;

X is hydrogen, O, N or N<sub>3</sub>;

X<sub>1</sub> is hydrogen, -CH<sub>2</sub>O-, -CH<sub>2</sub>NH-, -CH<sub>3</sub>, -CH<sub>2</sub>N<sub>3</sub> or -COO-; and

B, C, D and E are any protecting groups which can be cleaved orthogonally.

- 5 -

It will be appreciated that as a consequence of stoichiometry and valence bond theory B, C, D and E are absent when X is hydrogen or N<sub>3</sub> and E is absent when X<sub>1</sub> is hydrogen, CH<sub>3</sub> or N<sub>3</sub>.

5           The following non-limiting sets have been designated as orthogonal to each other on the basis of their cleavage conditions. A protecting group is classified in a particular set according to its lability to the cleavage conditions for a particular set and its  
10 stability to the cleavage conditions required for the removal of those groups in the remaining sets. Each set is to be taken to include, but is not be limited, by the members thereof.

          Of the sets defined, set 1, the 'Base Solvolysis' set, is of particular importance, because in addition to the fact that the members of this set are considered to be orthogonal to the members of the remaining sets, some members of this set are also considered to be orthogonal to each other. Where this is the case, the alternative  
15 condition of cleavage that provides orthogonality is specified in brackets following the listing of the protecting group.

20           1. Base Solvolysis

25           a) for hydroxy protection:

          acyl-type protecting groups, eg. chloroacetate  
          (also thiourea-sensitive)

          bromoacetate (also pyridine-sensitive)

30           carbonates, eg. Alloc (Pd<sup>0</sup>)

          Fmoc (β-elimination)

          Troc

          p-nitrophenylsulphonylethyloxy carbonyl)

          levanoyl (also hydrazine sensitive)

35

- 6 -

b) for amino protection:

Dde, Wow (primary amine-sensitive)

tetraphthaloyl

5 dichlorophthaloyl

2,5-dimethyl-pyrrolyl (primary amine-sensitive)

benzyloxycarbonyl

pentenyl

10 2. Fluoride Ion-Sensitive  
for hydroxy protection:

t-butyldiphenylsilyl

triisopropylsilyl

15 trimethylsilylethyl

triphenylsilylethyl

(all cleavable with HF/Pyridine)

20 3. Reduction-Sensitive

trifluoromethyl

trichloromethyloxymethyl

trichloromethyloxycarbonate

(all cleavable with zinc/acetic acid)

25

4.  $\beta$ -Elimination-Sensitive, Base-Labile Protecting Groups

ethoxyethyl

cyanoethyl

30 NSC (p-nitrobenzyl-sulphonylethyloxycarbonyl)

p-nitrobenzyl-sulphonylethyl

5. Hydrogenolysis-Sensitive Protecting Groups

35 naphthylmethyl

substituted naphthylmethyl

- 7 -

6. Oxidation-Sensitive Protecting Groups:

- 5 p-methoxybenzyl  
3,4-dimethoxybenzyl  
2,4,6-trimethoxybenzyl  
3,4-methylenedioxybenzyl  
acylamidobenzyl  
azidobenzyl  
p-azido-m-chlorobenzyl

10

7. Allylic Protecting Groups

Cleavable with Pd<sup>0</sup> complexes

15 8. Photolabile Protecting Groups:


- o-nitrobenzyloxycarbonate  
o-nitrobenzyl  
dinitrobenzyl  
20 2-oxo-1,2-diphenylethyl

9. Protecting Groups Removable by Relay Deprotection

- 25 methylthioethyl  
acyloxybenzyl  
benzylthioethyl.

In one preferred embodiment, the invention provides a compound of General Formula III

30



III


- 8 -

in which

A, X and X<sub>1</sub> are as defined for General Formulae I and II, and

B<sub>1</sub>, C<sub>1</sub>, D<sub>1</sub> and E<sub>1</sub> are orthogonal carbohydrate protecting groups (ie. an orthogonal set) selected from protecting group sets 1, 2, 6 and 8.

Another preferred embodiment provides a compound of General Formula IV




in which

A, X and X<sub>1</sub> are as defined for General Formulae I and II, and

B<sub>2</sub>, C<sub>2</sub>, D<sub>2</sub> and E<sub>2</sub> are selected from the members of protecting group set 1, and in themselves constitute an orthogonal set, for example the carbohydrate-protecting groups levanoyl (ammonia-labile), chloroacetate (thiourea-labile), *p*-methoxybenzyloxycarbonyl (oxidation-labile) and 2-trimethylsilylethylcarbonate (fluoride ion-labile).

This embodiment provides universal building blocks with protecting groups selected from the protecting groups of set 1.

In a third preferred embodiment the invention provides a compound of General Formula V



in which

A, X and X<sub>1</sub> are as defined for General Formula I and II, and

5 B<sub>3</sub>, C<sub>3</sub>, D<sub>3</sub> and E<sub>3</sub> are an orthogonal set of protecting groups selected from amongst the members of set 1 and from the remaining orthogonal sets.

This embodiment provides orthogonally protected building blocks, the protecting group constituents of which  
10 may be selected from within set 1 and from the remaining sets.

It will be clearly understood that the invention is not limited to use with monosaccharides, but is also applicable to any compound in which substituents are linked  
15 to a pyranose or furanose ring, such as sugar analogues.

For the purposes of this specification it will be clearly understood that the word "comprising" means "including but not limited to", and that the word "comprises" has a corresponding meaning.

20 For the purposes of this specification "orthogonal cleavage" is defined as the regioselective cleavage of a hydroxy or amino protecting group from a carbohydrate, in which the cleavage conditions do not compromise the stability of the other protecting or  
25 functional groups on the molecule. Such cleavages can be effected in any order of priority. "Cleaved orthogonally" and "orthogonal cleavage" are taken to be synonymous.

#### DETAILED DESCRIPTION OF THE INVENTION

30 Abbreviations used herein are as follows:

Alloc	Allyloxycarbonyl
Bn	Benzyl
Bu	Butyl
35 DCM	Dichloromethane
Dde	N-1-(4,4-Dimethyl-2,6-dioxocyclohexylidene)ethyl

- 10 -

	Dde-OH	6-Hydroxy-6-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl
	DMAP	<i>N,N'</i> -Dimethylaminopyridine
	DMF	<i>N,N'</i> -Dimethylformamide
5	DMTST	Dimethyl(methylthio)sulphoniumtrifluoromethane-sulphonate
	EEDQ	1-isobutyloxycarbonyl-2-isobutyloxy-1,2-dihydroquinoline
	EtOAc	Ethyl acetate
10	EtOH	Ethanol
	FAB-MS	Fast atom bombardment mass spectrometry
	HRMS	High resolution mass spectrometry
	Fmoc	Fluoromethoxycarbonyl
	MBHA	Methyl benzyhydramine resin
15	Me	Methyl
	MeOH	Methanol
	NCS	<i>p</i> -Nitrobenzyl-sulphonylethyloxycarbonyl
	NMR	Nuclear magnetic resonance
	ODmab	4-{ <i>N</i> -[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]-amino}benzyl alcohol
20	PEG	Polyethylene glycol
	tBu	Tertiary-butyl
	TFA	Trifluoroacetic acid
	THF	Tetrahydrofuran
25	Troc	2,2,2-Trichloroethoxycarbonyl


The invention provides universal building blocks, which are useful in the solution and solid phase synthesis of oligosaccharides. The reaction scheme for synthesis of each target molecule is designed so as to specify the orthogonally-protected functional groups which must be freed for glycosylation, and those which need to be capped with a protecting group such as benzyl, benzoyl, or another such group which remains uncleaved until the end of the synthesis, in order to avoid competition during glycosylations later in the synthesis.

- 11 -

When participation during the glycosylation reaction is required, the 2-hydroxyl is selectively deprotected and re-protected with a benzoyl group which, again, remains until the completion of the synthesis. In the case of 2-deoxy 2-aminosugars, if participation or stereoselectivity is required the Dde group might be removed and replaced with a tetrachlorophthaloyl or 2,5-dimethylpyrrole group.


10 **Example 1      Synthesis of an Exemplary Tetrasaccharide**

A strategy for synthesis of the tetrasaccharide of formula VI is set out in Scheme 1.



VI

- 12 -




- 13 -

In solution phase, protecting groups A and C from the first sugar residue of the target molecule (residue [4]) are selectively removed, and the sites capped by a permanent protecting group, eg. benzoyl group. The residue is then coupled to the resin, followed by selective removal of protecting group B. In solution phase, protecting group A from sugar residue [3] is selectively removed, and the site is capped by a permanent protecting group. Residue [3] is then linked to the resin-bound sugar residue via a glycosylation reaction. Protecting group C from the new disaccharide is removed, and residue [2] is linked via a glycosylation. Protecting group A is finally selectively removed to regenerate the 6-hydroxyl group, which is linked with residue 1.

15

**Example 2**      **Synthesis of an Orthogonally Protected Thioglycoside Building Block, Methyl 6-O-(t-butyldiphenylsilyl)-3-O-(p-chlorobenzoyl)-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-4-O-tetrahydropyranyl-1-thio- $\beta$ -D glucopyranoside (5)**



**10**      **Methyl 4,6-O-benzylidene-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-thio- $\beta$ -D glucopyranoside (1)**

A mixture of methyl 2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-thio- $\beta$ -D glucopyranoside (20 g, 54 mmol),  $\alpha,\alpha$ -dimethoxytoluene (9.78 g, 64 mmol) and p-toluenesulphonic acid (50 mg) in dry acetonitrile (100 mL), was stirred at 60°C for 2 hours. The reaction mixture was cooled to room temperature and adjusted to pH 7 with the addition of triethylamine. The solvent was removed in vacuo, the residue was taken up in  $\text{CH}_2\text{Cl}_2$  (200 mL), washed with brine (50 mL), with water

- 15 -

(50 ml) and dried over  $\text{MgSO}_4$ . The organic phase was concentrated to give a yellow solid, methyl 4,6-O-benzylidene-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-thio- $\beta$ -D glucopyranoside (24.5 g, 98%).

**Methyl 4,6-O-benzylidene-3-O-(p-chlorobenzoyl)-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-thio- $\beta$ -D glucopyranoside (2)**

10

A mixture of methyl 4,6-O-benzylidene-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-thio- $\beta$ -D-glucopyranoside (1) (6.3 g, 13.5 mmol), p-chlorobenzoylchloride (2.6 ml, 20 mmol) and 4-dimethylaminopyridine (2.44 g, 40 mmol) in dry 1,2-dichloroethane (100 ml), was stirred at room temperature overnight. The resultant suspension was filtered, the filtrate diluted with chloroform (100 ml) and washed with diluted brine (3 x 50 ml,  $\text{H}_2\text{O}$ /Brine, 2/1). The organic phase was dried over  $\text{MgSO}_4$  and the solvent removed *in vacuo* to give yellow solid. The residue chromatographed EtOAc/Hexane 1:1 as the mobile phase to give methyl 4,6-O-benzylidene-3-O-(p-chlorobenzoyl)-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-thio- $\beta$ -D-glucopyranoside (2) (6.4 g, 80%).

30

**Methyl 3-O-(p-chlorobenzoyl)-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-thio- $\beta$ -D glucopyranoside (3)**

A mixture of methyl 4,6-O-benzylidene-3-O-(p-chlorobenzoyl)-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-thio- $\beta$ -D

- 16 -

glucopyranoside (2) (2.51 g, 4.20 mmol) and 50% aqueous solution of tetrafluoroboric acid (1 ml) in acetonitrile (25 mL), was stirred at room temperature for 2 hours. The pH was adjusted to 7 with the addition of triethylamine and the resultant suspension concentrated. The residue was crystallised from diisopropyl ether-ethyl acetate to give methyl 3-O-(p-chlorobenzoyl)-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-thio- $\beta$ -D glucopyranoside (3) (1.7 g, 79%).

**Methyl 6-O-(t-butyldiphenylsilyl)-3-O-(p-chlorobenzoyl)-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-thio- $\beta$ -D glucopyranoside (4)**

A mixture of methyl 3-O-(p-chlorobenzoyl)-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-ethylamino]-1-thio- $\beta$ -D-glucopyranoside (3) (1.00 g, 1.95 mmol), t-butyldiphenylsilylchloride (536 mg, 1.95) and 4-dimethylaminopyridine (238 mg, 1.95 mmol), in 1,2-dichloroethane (30 mL), was stirred under reflux for 6 hours. The reaction mixture was cooled to room temperature, diluted with chloroform (60 mL) and washed with diluted brine (3 x 50 mL, brine/water, 1:2), dried over  $\text{MgSO}_4$ . The solvent was removed in vacuo and the residue was chromatographed using hexane - EtOAc 1:1 as the mobile phase to give a white solid, methyl 6-O-(t-butyldiphenylsilyl)-3-O-(p-chlorobenzoyl)-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-thio- $\beta$ -D-glucopyranoside (4) (1.1 g, 75%).


- 17 -

Methyl 6-O-(t-butyldiphenylsilyl)-3-O-(p-chlorobenzoyl)-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-4-O-tetrahydropyranyl-1-thio- $\beta$ -D  
5 glucopyranoside (5)

A mixture of methyl 6-O-(t-butyldiphenylsilyl)-3-O-(p-chlorobenzoyl)-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-thio- $\beta$ -D-  
10 glucopyranoside (500 mg, 0.6 mmol), 3,4-dihydro-2H-pyran (5 mL) and p-toluenesulphonic acid (5 mg) in dry acetonitrile (10 mL) was stirred at room temperature for 1 hour. The reaction mixture was adjusted to pH 7 with the addition of triethylamine and then evaporated to dryness.  
15 The residue was taken up in dichloromethane (30 mL), washed with water (2 x 10 mL) and the organic phase dried over  $\text{MgSO}_4$ . The solvent was removed *in vacuo* and the residue was chromatographed using hexane - EtOAc 2:1 as the mobile phase to give methyl 6-O-(t-butyldiphenylsilyl)-3-O-(p-  
20 chlorobenzoyl)-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-4-O-tetrahydropyranyl-1-thio- $\beta$ -D-glucopyranoside (5) (420 mg, 85%).

**Example 3**      **Synthesis of an Orthogonally Protected Thioglycoside Building Block, methyl 2-azido-6-O-(t-butyldiphenylsilyl)-2-deoxy-3-O-(4-methoxybenzyl)-4-O-biphenylcarbonyl-1-thio- $\beta$ -D glucopyranoside**

5



**Methyl 2-azido-4,6-O-benzylidene-2-deoxy-1-thio- $\beta$ -D glucopyranoside (7)**

10

A mixture of methyl 2-azido-2-deoxy-1-thio- $\beta$ -D glucopyranoside (**6**) (10g, 4.25 mmol),  $\alpha,\alpha$ -dimethoxytoluene (9.71 g, 64 mmol) and p-toluenesulphonic acid (50 mg) in dry acetonitrile (100 mL), was stirred at 60°C for 2 hours. The reaction mixture was cooled to room temperature and adjusted to pH 7 with the addition of triethylamine. The solvent was removed *in vacuo*. The residue was taken up in CH<sub>2</sub>Cl<sub>2</sub> (200 mL), washed with brine (50 mL), with water (50 mL) and dried over MgSO<sub>4</sub>. The organic phase was concentrated to give a white solid, methyl 2-azido-4,6-O-benzylidene-2-deoxy-1-thio- $\beta$ -D glucopyranoside (**7**) (10.5 g, 73%).

- 19 -

**Methyl 2-azido-4,6-O-benzylidene-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D glucopyranoside (8)**

A suspension of sodium hydride (1.0 g, 41.8 mmol) in dry  
5 DMF (50 mL) was cooled to 0 °C, and a solution of methyl 2-azido-4,6-O-benzylidene-2-deoxy-1-thio- $\beta$ -D glucopyranoside (7) (9.0 g, 27.8 mmol) in dry DMF (50 mL) was added dropwise in 30 minutes. The resulting solution was stirred at 0 °C for 30 minutes and 4-methoxybenzyl chloride (6.54  
10 g, 41.8 mmol) was added dropwise at 0 °C. The reaction mixture was stirred at room temperature overnight, cooled to 0 °C and dry methanol (5 mL) was added dropwise. The reaction mixture was concentrated under reduced pressure, then xylene (50 mL) was co-evaporated from the residue. The  
15 residue was taken up in CHCl<sub>3</sub> (200 mL) washed with H<sub>2</sub>O (400 ml), saturated NaHCO<sub>3</sub> solution (200 mL) dried over MgSO<sub>4</sub> and evaporated to dryness. The residue was crystallized from EtOH to give methyl 2-azido-4,6-O-benzylidene-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (8) (9,0  
20 g, 73%) as white crystalline solid.

**Methyl 2-azido-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (9)**

25 A mixture of methyl 2-azido-4,6-O-benzylidene-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D glucopyranoside (8) (12.0 g, 27.08 mmol) and p-toluenesulphonic acid (300 mg) in MeOH - MeCN 1:1 (400 mL) was stirred at 50 C° for 1 hour. The reaction mixture was evaporated, the residue was  
30 chromatographed using CHCl<sub>3</sub> - EtOAc gradient to give methyl 2-azido-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (9) (8.21 g, 88%).

- 20 -

**Methyl 2-azido-6-O-tert-butyldiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D glucopyranoside (10)**

A mixture of t-butyldiphenylsilyl chloride (8.66 g, 31.53 mmol), 4-dimethylaminopyridine (5.12 g, 42.04 mmol) and methyl 2-azido-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (9) (7.21 g, 21.02 mmol) in dry 1,2-dichloroethane (100 mL) was stirred at 80°C for 2 hours. The resulting clear solution was cooled to room temperature, diluted with  $\text{CHCl}_3$  (300 mL), washed with  $\text{H}_2\text{O}$  (3 x 200 mL), brine solution (200 mL), dried over  $\text{MgSO}_4$  and evaporated. The residue was purified by chromatography using hexane - ether 2:1 as the mobile phase to give methyl 2-azido-6-O-tert-butyldiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D glucopyranoside (10) (9.73 g, 80%).


**Methyl 2-azido-6-O-tert-butyldiphenylsilyl-4-O-biphenylcarbonyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D glucopyranoside (11)**

A mixture of methyl 2-azido-6-O-tert-butyldiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D glucopyranoside (10) (12.7 g, 21.46 mmol), 4-dimethylaminopyridine (5.23 g, 42.92 mmol) in dry 1,2-dichloroethane (100 mL) was stirred at room temperature. Biphenylcarbonyl chloride (6.97 g, 32.19 mmol) was added to the stirred reaction mixture in 15 minutes. After the addition the resulting suspension was stirred under reflux for 3 hours. The reaction mixture was cooled to 10°C and filtered. The crystalline solid was washed on the funnel with dry 1,2-dichloroethane (50 mL) and filtered. The filtrates were combined, diluted with  $\text{CHCl}_3$  (200 mL) and washed twice with diluted brine solution (water-brine 2:1) (150 mL). The organic layer was dried over  $\text{MgSO}_4$  and evaporated. The residue was crystallized from EtOH (75 mL) to give methyl 2-azido-6-O-tert-

- 21 -

butyldiphenylsilyl-4-O-biphenylcarbonyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (11) (12.7 g, 76%)

5 **Example 4 Synthesis of an Orthogonally Protected Thioglycoside Building Block, methyl 2-azido-6-O-(t-butyldiphenylsilyl)-2-deoxy-3-O-(4-methoxybenzyl)-4-O-biphenylcarbonyl-1-thio- $\beta$ -D-galactopyranoside (17)**



10

**Methyl 2-azido-4,6-O-benzylidene-2-deoxy-1-thio- $\beta$ -D-galactopyranoside (13)**

- 15 A mixture of methyl 2-azido-2-deoxy-1-thio- $\beta$ -D-galactopyranoside (**12**) (3.0 g, 12.76 mmol),  $\alpha,\alpha$ -dimethoxytoluene (2.91 g, 19.14 mmol) and p-toluenesulphonic acid (30 mg) in dry acetonitrile (15 mL), was stirred at 70°C for 20 minutes. The reaction mixture
- 20 was cooled to room temperature and adjusted to pH 7 with the addition of triethylamine. The solvent was removed in vacuo and the residue was taken up in  $\text{CH}_2\text{Cl}_2$  (100 mL), washed with brine (50 mL), with water (50 mL) and dried over  $\text{MgSO}_4$ . The organic phase was concentrated to give a

- 22 -

white solid, methyl 2-azido-4,6-O-benzylidene-2-deoxy-1-thio- $\beta$ -D-galactopyranoside (**13**) (3.09 g, 75%).

**Methyl 2-azido-4,6-O-benzylidene-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-galactopyranoside (**14**)**

A suspension of sodium hydride (123 mg, 4.87 mmol) in dry DMF (10 mL) was cooled to 0 °C, and a solution of methyl 2-azido-4,6-O-benzylidene-2-deoxy-1-thio- $\beta$ -D-galactopyranoside (**13**) (1.05 g, 3.25 mmol) in dry DMF (10 mL) was added dropwise in 30 minutes. The resulting solution was stirred at 0 °C for 30 minutes and 4-methoxybenzyl chloride (763 mg, 4.87 mmol) was added dropwise at 0 °C. The reaction mixture was stirred at room temperature overnight, cooled to 0 °C and dry methanol (2 mL) was added dropwise. The reaction mixture was concentrated under reduced pressure, then xylene (25 mL) was co-evaporated from the residue. The residue was taken up in CHCl<sub>3</sub> (50 mL) washed with H<sub>2</sub>O (40 mL), saturated NaHCO<sub>3</sub> solution (50 mL) dried over MgSO<sub>4</sub> and evaporated to dryness. The residue was crystallized from EtOH (10 mL) to give methyl 2-azido-4,6-O-benzylidene-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-galactopyranoside (**14**) (1.0 g, 70%) as white crystalline solid.

25

**Methyl 2-azido-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-galactopyranoside (**15**)**

A mixture of methyl 2-azido-4,6-O-benzylidene-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-galactopyranoside (**14**) (500 mg, 1.12 mmol) and p-toluenesulphonic acid (10 mg) in MeOH - MeCN 1:1 (50 mL) was stirred at 50 °C for 1 hour. The reaction mixture was evaporated, the residue was

- 23 -

chromatographed using CHCl<sub>3</sub> - EtOAc gradient to give methyl 2-azido-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-galactopyranoside (**15**) (309 mg, 80%)

5 **Methyl 2-azido-6-O-tert-butyldiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-galactopyranoside (**16**)**

A mixture of t-butyldiphenylsilyl chloride (151 mg, 0.54 mmol), 4-dimethylaminopyridine (90 mg, 0.73 mmol)  
10 and methyl 2-azido-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-galactopyranoside (**15**) (130 mg, 0.36 mmol) in dry 1,2-dichloroethane (8 mL) was stirred at 80°C for 2 hours. The resulting clear solution was cooled to room temperature, diluted with CHCl<sub>3</sub> (20 mL), washed with H<sub>2</sub>O (3 x 20 mL),  
15 brine solution (20 mL), dried over MgSO<sub>4</sub> and evaporated. The residue was purified by chromatography using hexane - ether 2:1 as the mobile phase to give methyl 2-azido-6-O-tert-butyldiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-galactopyranoside (**16**) (142 mg, 68%).


20 **Methyl 2-azido-6-O-tert-butyldiphenylsilyl-4-O-biphenylcarbonyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-galactopyranoside (**17**)**

25 A mixture of methyl 2-azido-6-O-tert-butyldiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-galactopyranoside (**16**) (213 mg, 0.36 mmol), 4-dimethylaminopyridine (67 mg, 0.55 mmol) in dry 1,2-dichloroethane (10 mL) was stirred at room temperature. Biphenylcarbonyl chloride (119 mg, 0.55  
30 mmol) was added to the stirred reaction mixture. The resulting suspension was stirred under reflux for 3 hours. The reaction mixture was cooled to 10°C and filtered. The crystalline solid was washed on the funnel with dry 1,2-dichloroethane (5 mL) and filtered. The filtrates were

- 24 -

combined, diluted with  $\text{CHCl}_3$  (20 mL) and washed twice with diluted brine solution (water-brine 2:1) (15 mL). The organic layer was dried over  $\text{MgSO}_4$  and evaporated. The residue was purified by chromatography using hexane -  $\text{CHCl}_3$  1:1 as the mobile phase to give methyl 2-azido-6-O-tert-butyl-  
 5 butyldiphenylsilyl-4-O-biphenylcarbonyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-galactopyranoside (**17**) (180 mg, 65%).

- 10 **Example 5**      **Synthesis of an Orthogonally Protected Thioglycoside Building Block, Methyl 6-O-(t-butyldiphenylsilyl)-2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-3-O-(4-methoxybenzyl)-4-O-biphenylcarbonyl-1-thio- $\beta$ -D-glucopyranoside (**23**)**



- 25 -

**Methyl 2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-1-thio- $\beta$ -D-glucopyranoside (19)**

5 To methyl 2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-ethylamino]-1-thio- $\beta$ -D-glucopyranoside (**18**) (100 g, 268 mmol) was added conc. ammonia solution (300 mL) and the reaction mixture was stirred at 100 C° for 1 hour. The suspension was cooled to room temperature and filtered. The  
10 filtrate was washed with CHCl<sub>3</sub> (3x200 mL), then the aqueous phase was evaporated under reduced pressure. The residue was taken up in EtOH : benzene 1:1 (250 mL) and evaporated to dryness.

The residue was taken up in hot MeOH (600 mL) and 1, 3-  
15 dimethyl-5-[(dimethylamino)methylene]2, 4, 6 (1H, 3H, 5H)-trioxypyrimidine (Wow-reagent) (62.27 g, 294.9 mmol) in hot MeOH (120 mL) was added. /Synthesis of 1, 3-Dimethyl-5-[(dimethylamino)methylene]2, 4, 6 (1H, 3H, 5H)-trioxypyrimidine (Wow-reagent): N, N-Dimethylformamide  
20 dimethyl acetal (252 g, 2.11 mol) was stirred at 0°C in CHCl<sub>3</sub> (750 mL). 1, 3-Dimethylbarbituric acid (300 g, 1.92 mol) in CHCl<sub>3</sub> (2100 mL) was added to the stirring acetal solution over 2 hours. The CHCl<sub>3</sub> was evaporated immediately following complete addition and the resulting residue re-  
25 suspended in CHCl<sub>3</sub> (2000 mL) and washed with water (3x600 mL) and saturated brine solution (600 mL). The organic phase was dried over MgSO<sub>4</sub>, filtered and evaporated to dryness under high vacuum. The residue was re-suspended in diethyl ether (750 mL), filtered and washed on the funnel  
30 with additional diethyl ether (500 mL) to yield 1, 3-Dimethyl-5-[(dimethylamino)methylene]2, 4, 6 (1H, 3H, 5H)-trioxypyrimidine as a pale-yellow solid (271.85 g, 67%). / The reaction mixture was stirred under reflux for 30 minutes, then cooled to room temperature. The resulting  
35 suspension was filtered, the solid was washed with MeOH (150 mL), ether (150 mL), dried to give methyl 2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-

- 26 -

ylidene)methylamino]-1-thio- $\beta$ -D-glucopyranoside (**19**) (83 g, 90%).

5     **Methyl 4,6-O-benzylidene-2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-1-thio- $\beta$ -D-glucopyranoside (**20**)**

10     A mixture of methyl 2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-1-thio- $\beta$ -D-glucopyranoside (**19**) (84.64 g, 226.31 mmol),  $\alpha,\alpha$ -dimethoxytoluene (51.66 g, 339.46 mmol) and p-toluenesulphonic acid (500 mg) in dry acetonitrile (600 mL), was stirred at 60°C for 2 hours. The reaction mixture was cooled to room temperature and filtered. The  
15     solid was washed with ether (200 mL), dried to give methyl 4,6-O-benzylidene-2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-1-thio- $\beta$ -D-glucopyranoside (**20**) (80 g, 77%).

20     **Methyl 4,6-O-benzylidene-2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**21**)**

25     A suspension of sodium hydride (6.82 g, 269.97 mmol) in dry DMF (50 mL) was cooled to 0 °C, and a solution of methyl 4,6-O-benzylidene-2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-1-thio- $\beta$ -D-glucopyranoside (**20**) (50 g, 107.99 mmol in dry DMF (200 mL) was added dropwise in 30 minutes. The resulting solution  
30     was stirred at room temperature for 30 minutes and 4-methoxybenzyl chloride (37.36 g, 238.56 mmol) was added dropwise at 0 °C. The reaction mixture was stirred at room temperature overnight, cooled to 0 °C and dry methanol (10 mL) was added dropwise. The reaction mixture was

- 27 -

concentrated under reduced pressure, then xylene (200 mL) was co-evaporated from the residue. The residue was taken up in  $\text{CHCl}_3$  (1000 mL) washed with  $\text{H}_2\text{O}$  (1000 mL), saturated  $\text{NaHCO}_3$  solution (1000 mL) dried over  $\text{MgSO}_4$  and evaporated to dryness. The residue was crystallized from EtOH to give methyl 4,6-O-benzylidene-2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**21**) (52.21 g, 82%).

10

**Methyl 2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**22**)**

15 A mixture of methyl 4,6-O-benzylidene-2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**21**) (52.21 g, 89.55 mmol and p-toluenesulphonic acid (200 mg) in MeOH - MeCN 1:1 (400 mL) was stirred at 50 °C for 1 hour. The reaction mixture was evaporated, the residue was chromatographed using  $\text{CHCl}_3$  - MeOH 10:1 as the mobile phase to give methyl 2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**22**) (31.0 g, 70%)

25

**Methyl 6-O-tert-butyldiphenylsilyl-2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**23**)**

30

A mixture of t-butyldiphenylsilyl chloride (16.65 g, 60.60 mmol), 4-dimethylaminopyridine (9.85 g, 80.80 mmol) and methyl 2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-

- 28 -

trioxopyrimidin-5-ylidene)methylamino]-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**22**) (20 g, 40.4 mmol) in dry 1,2-dichloroethane (200 mL) was stirred at 80°C for 2 hours. The resulting clear solution was cooled to room temperature, diluted with CHCl<sub>3</sub> (200 mL), washed with H<sub>2</sub>O (3 x 500 mL), brine solution (500 mL), dried over MgSO<sub>4</sub> and evaporated. The residue was purified by chromatography using 1,2-dichloroethane - EtOAc 10:1 as the mobile phase to give methyl 6-O-tert-butyldiphenylsilyl-2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylamino]-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**23**) (23.3 g, 79%).

**Methyl 6-O-tert-butyldiphenylsilyl-4-O-biphenylcarbonyl-2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylamino]-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**24**)**


A mixture of methyl 6-O-tert-butyldiphenylsilyl-2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylamino]-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**23**) (10.0 g, 13.64 mmol), 4-dimethylaminopyridine (2.5 g, 20.46 mmol) in dry 1,2-dichloroethane (100 mL) was stirred at room temperature. Biphenylcarbonyl chloride (4.42 g, 20.46 mmol) was added to the stirred reaction mixture. The resulting suspension was stirred under reflux for 3 hours. The reaction mixture was cooled to 10°C and filtered. The crystalline solid was washed on the funnel with dry 1,2-dichloroethane (20 mL) and filtered. The filtrates were combined, diluted with CHCl<sub>3</sub> (100 mL) and washed twice with diluted brine solution (water-brine 2:1) (150 mL). The organic layer was dried over MgSO<sub>4</sub> and evaporated. The residue was purified by chromatography using hexane - CHCl<sub>3</sub> 1:1 as the mobile phase to give methyl 6-O-tert-butyldiphenylsilyl-4-O-

biphenylcarbonyl-2-deoxy-2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**24**) (9.5 g, 75%).

5

**Example 6**      **Synthesis of an Orthogonally Protected Thioglycoside Building Block, Methyl 6-O-(*t*-butyldiphenylsilyl)-2-O-(4-methoxybenzyl)-3-O-allyl-4-O-acetyl-1-thio- $\beta$ -D-galactopyranoside (**6**)**

10



**Methyl 6-O-(*t*-butyldiphenylsilyl)-1-thio- $\beta$ -D-galactopyranoside (**26**)**

A mixture of methyl 1-thio- $\beta$ -D-galactopyranoside (**25**) (5 g, 28 mmol), chloro *t*-butyldiphenylsilane (5.85 g, 21 mmol) and DMAP (2.63 g, 21 mmol) in dry 1, 2-dichloroethane (130 mL) was left to stir at reflux for 2.5 h. The reaction mixture was cooled to room temperature, diluted with dichloromethane (200 mL) and washed with saturated sodium chloride solution (2 x 250 mL). The organic phase was dried over  $\text{MgSO}_4$  and subsequently evaporated to dryness to

- 30 -

give methyl 6-*O*-(*t*-butyldiphenylsilyl)-1-thio- $\beta$ -D-galactopyranoside (**26**) (7.5 g, 81%) as a colorless oil.

**Methyl 6-*O*-(*t*-butyldiphenylsilyl)-3,4-*O*-isopropylidene-1-thio- $\beta$ -D-galactopyranoside (**27**)**

A mixture of methyl 6-*O*-(*t*-butyldiphenylsilyl)-1-thio- $\beta$ -D-galactopyranoside (**26**) (7.4 g, 16.5 mmol) and *p*-toluenesulphonic acid (20 mg) in 2,2-dimethoxypropane (100 mL) was left to stir at room temperature for 2 h. The reaction mixture was then neutralized with triethylamine (1 mL) and evaporated to dryness. The residue was dissolved in dichloromethane (250 mL), washed with water (1 x 250 mL), dried over MgSO<sub>4</sub> and evaporated to dryness to give methyl 6-*O*-(*t*-butyldiphenylsilyl)-3,4-*O*-isopropylidene-1-thio- $\beta$ -D-galactopyranoside (**27**) (7.0 g, 87%) as a white solid.

**Methyl 6-*O*-(*t*-butyldiphenylsilyl)-2-*O*-(4-methoxybenzyl)-3,4-*O*-isopropylidene-1-thio- $\beta$ -D-galactopyranoside (**28**)**

To a suspension of sodium hydride (95%, 0.53 g, 21 mmol) in dry DMF (100 mL) at 0° C°, was added dropwise methyl 6-*O*-(*t*-butyldiphenylsilyl)-3,4-*O*-isopropylidene-1-thio- $\beta$ -D-galactopyranoside (**27**) (6.8 g, 13.9 mmol) as a solution in dry DMF (25 mL) in 5 minutes. The resulting mixture was left to stir at 0 C° for 15 min and then at room temperature for 1 h. The mixture was then cooled to 0 C° and a solution of 4-methoxybenzyl chloride (3.27 g, 21 mmol) in dry DMF (25 mL) was added dropwise, over 5 min. The reaction mixture was left to stir at 0° C for 15 min and then at room temperature for 16 h. After this period the reaction was neutralized with absolute ethanol (15 mL) at 0° C, and then evaporated to dryness. The residue was taken up in chloroform (400 mL), washed with water (300 mL)

- 31 -

and saturated sodium bicarbonate solution (300 mL). The organic phase was dried over  $\text{MgSO}_4$  and evaporated to dryness to give the crude product as an orange oil (~9 g). The crude material was chromatographed using EtOAc - hexane 5 25 : 75 as the mobile phase to give methyl 6-O-(*t*-butyldiphenylsilyl)-2-O-(4-methoxybenzyl)-3,4-O-isopropylidene-1-thio- $\beta$ -D-galactopyranoside (**28**) as a pale yellow oil (6.5 g, 77%).

10

**Methyl 6-O-(*t*-butyldiphenylsilyl)-2-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-galactopyranoside (**29**)**

A suspension of methyl 6-O-(*t*-butyldiphenylsilyl)-2-O-(4-methoxybenzyl)-3,4-O-isopropylidene-1-thio- $\beta$ -D-galactopyranoside (**28**) (6.4 g, 10.5 mmol) in acetic acid 15 (80%, 150 mL) was left to stir at 70 °C for 1.5 h. The reaction mixture was evaporated to dryness and the remaining residue was chromatographed using EtOAc - hexane 1 : 1 to give methyl 6-O-(*t*-butyldiphenylsilyl)-2-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-galactopyranoside (**29**) as a pale 20 yellow oil (3.0 g, 50%).

**Methyl 6-O-(*t*-butyldiphenylsilyl)-2-O-(4-methoxybenzyl)-3-O-allyl-1-thio- $\beta$ -D-galactopyranoside (**30**)**

A mixture of methyl 6-O-(*t*-butyldiphenylsilyl)-2-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-galactopyranoside (**29**) (2.8 g, 4.9 mmol) and dibutyl tin oxide (1.6 g, 6.4 mmol) in anhydrous methanol (200 mL) was stirred at reflux for 1 h. The reaction mixture was evaporated to dryness and the 25 remaining residue dissolved in dry toluene (50 mL). Tetraethylammonium bromide (1.34 g, 6.4 mmol) and allyl bromide (7.7 g, 64 mmol) were added. The reaction mixture was left to stir at reflux overnight. The reaction mixture 30

- 32 -


was cooled to room temperature and filtered. The filtrate was evaporated to dryness and the residue was purified by chromatography using EtOAc - hexane 15 : 85 as the mobile phase to give methyl 6-O-(*t*-butyldiphenylsilyl)-2-O-(4-methoxybenzyl)-3-O-allyl-1-thio- $\beta$ -D-galactopyranoside (**30**) (1.5 g, 50%) as a pale yellow oil.

**Methyl 6-O-(*t*-butyldiphenylsilyl)-2-O-(4-methoxybenzyl)-3-O-allyl-4-O-acetyl-1-thio- $\beta$ -D-galactopyranoside (**31**)**

To a solution of methyl 6-O-(*t*-butyldiphenylsilyl)-2-O-(4-methoxybenzyl)-3-O-allyl-1-thio- $\beta$ -D-galactopyranoside (**30**) (1.4 g, 2.3 mmol) in pyridine (30 mL) was added acetic anhydride (20 g, 196 mmol) in one portion. The resulting solution was left to stir at room temperature for 72 h. The reaction contents were then evaporated to dryness and the residue was dissolved in dichloromethane (200 mL). The solution was washed with potassium hydrogen sulphate solution (1M, 2 x 150 mL) followed by saturated sodium chloride (150 mL), dried over MgSO<sub>4</sub> and evaporated to dryness. The crude residue was purified by chromatography using dichloromethane as the mobile phase to give Methyl 6-O-(*t*-butyldiphenylsilyl)-2-O-(4-methoxybenzyl)-3-O-allyl-4-O-acetyl-1-thio- $\beta$ -D-galactopyranoside (**31**) (750 mg, 48%) as a pale yellow oil.

**Example 7      Selective Deprotection - Etherification study using an Orthogonally Protected Thioglycoside Building Block, Methyl 2-azido-6-O-*tert*-butyldiphenylsilyl-4-O-biphenylcarbonyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D glucopyranoside (**11**)**

- 33 -



**Methyl 2-azido-6-O-tert-butyl-diphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio-β-D-glucopyranoside (10)**

- 5 Sodium (89 mg) was reacted in dry MeOH (50 mL) then a solution of methyl 2-azido-4-O-biphenylcarbonyl-6-O-tert-butyl-diphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio-β-D-glucopyranoside (11) (3 g, 3.88 mmol) in THF (25 mL) was added. The reaction mixture was stirred at 40 C° for 30 minutes, then cooled to room temperature. The solution was

- 34 -

neutralized by Amberlite IR 120 (H<sup>+</sup>) ion exchange resin. The suspension was filtered, the filtrate was evaporated. The residue was purified by chromatography using EtOAc - hexane 1 : 4 as the mobile phase to give methyl 2-azido-6-O-tert-butyldiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio-β-D-glucopyranoside (**10**) (2.1 g, 91%)

**Methyl 2-azido-4-O-benzyl-6-O-tert-butyldiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio-β-D-glucopyranoside (32)**

A suspension of sodium hydride (196 mg, 5.1 mmol) in dry DMF (10 mL) was cooled to 0 °C, and a solution of methyl 2-azido-6-O-tert-butyldiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio-β-D-glucopyranoside (**10**) (2.53 g, 4.3 mmol) in dry DMF (20 mL) was added dropwise in 30 minutes. The resulting solution was stirred at room temperature for 30 minutes and benzyl bromide (880 mg, 5.1 mmol) was added dropwise at 0 °C. The reaction mixture was stirred at room temperature overnight, cooled to 0 °C and dry methanol (1 mL) was added dropwise. The reaction mixture was concentrated under reduced pressure, then xylene (20 mL) was co-evaporated from the residue. The residue was taken up in CHCl<sub>3</sub> (100 mL) washed with H<sub>2</sub>O (100 mL), saturated NaHCO<sub>3</sub> solution (100 mL) dried over MgSO<sub>4</sub> and evaporated to dryness. The residue was purified by chromatography using EtOAc - Hexane 1 : 9 as the mobile phase to give methyl 2-azido-4-O-benzyl-6-O-tert-butyldiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio-β-D-glucopyranoside (**32**) (2.0 g, 68%).

**Methyl 2-azido-4-O-benzyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio-β-D-glucopyranoside (33)**

To a mixture of methyl 2-azido-4-O-benzyl-6-O-tert-butyldiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio-β-D-glucopyranoside (**32**) (1.5 g, 2.2 mmol) and anhydrous AcOH (28.8 mL) in dry THF (169 mL) hydrogen fluoride-pyridine complex (20.3 mL) was added in a polypropylene container. The reaction mixture was kept at room temperature

- 35 -

overnight, then diluted with EtOAc (1 L). The resulting solution was washed with saturated sodium hydrogen carbonate (4 x 1 L), saturated brine solution (1 L), dried over MgSO<sub>4</sub> and evaporated to dryness. The residue was  
5 crystallized from MeOH. The mother liquor was evaporated, the residue was treated with hexane to get more solid. The solid products were combined affording methyl 2-azido-4-O-benzyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**33**) (735 mg, 75%).

10 **Methyl 2-azido-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**34**)**

A suspension of sodium hydride (71 mg, 1.8 mmol) in dry DMF (5 mL) was cooled to 0 °C, and a solution of methyl 2-  
15 azido-4-O-benzyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**33**) (680 mg, 1.5 mmol) in dry DMF (5 mL) was added dropwise in 30 minutes. The resulting solution was stirred at room temperature for 30 minutes and 4-chlorobenzyl chloride (295 mg, 1.5 mmol) was added dropwise  
20 at 0 °C. The reaction mixture was stirred at room temperature for 4.5 hours, cooled to 0 °C and dry methanol (1 mL) was added dropwise. The reaction mixture was concentrated under reduced pressure, then xylene (10 mL) was co-evaporated from the residue. The residue was treated  
25 with hexane (10 mL) and filtered to give methyl 2-azido-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**34**) (620 mg, 71 %).

30 **Methyl 2-azido-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-1-thio- $\beta$ -D-glucopyranoside (**35**)**

A mixture of methyl 2-azido-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D  
35 glucopyranoside (**34**) (580 mg, 1.01 mmol) and DDQ (270 mg, 1.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> - H<sub>2</sub>O 9:1 (10 mL) was stirred at room temperature for 3 hours. The reaction mixture was washed with saturated NaHCO<sub>3</sub> solution (3 x 15 ml), dried over

- 36 -

MgSO<sub>4</sub> and evaporated. The residue was purified by chromatography using CHCl<sub>3</sub>-Hexane-MeOH 30:20:0.5 as the mobile phase to give methyl 2-azido-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-1-thio- $\beta$ -D glucopyranoside (**35**) (300 mg, 66%).

**Methyl 2-azido-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-3-O-pentamethylbenzyl-1-thio- $\beta$ -D-glucopyranoside (**36**)**

A suspension of sodium hydride (40 mg, 1.0 mmol, 60%) in dry DMF (5 mL) was cooled to 0 °C, and a solution of methyl 2-azido-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-1-thio- $\beta$ -D glucopyranoside (**35**) (280 mg, 0.67 mmol) in dry DMF (5 mL) was added dropwise in 30 minutes. The resulting solution was stirred at room temperature for 30 minutes and pentamethylbenzyl chloride (200 mg, 1.0 mmol) was added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 4 hours, cooled to 0 °C and dry methanol (1 mL) was added dropwise. The reaction mixture was concentrated under reduced pressure then xylene (10 mL) was co-evaporated from the residue. The residue was in EtOAc (100 mL), washed with brine (2 x 100 mL), dried over MgSO<sub>4</sub> and evaporated. The resulting solid was suspended in hexane (50 mL) and filtered to give methyl 2-azido-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-3-O-pentamethylbenzyl-1-thio- $\beta$ -D glucopyranoside (**36**) (290 mg, 76%).

**2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-ethyl 2-azido-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-3-O-pentamethylbenzyl- $\alpha$ , $\beta$ -D-glucopyranoside (**37**)**

A mixture of methyl 2-azido-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-3-O-pentamethylbenzyl-1-thio- $\beta$ -D glucopyranoside (**36**) (220 mg, 0.36 mmol), 2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-ethanol (150 mg, 0.66 mmol), molecular sieves 4A (1 g) and DMTST (138 mg, 0.66 mmol) in 1,2-dichloroethane (10 mL) was stirred at room temperature for 30 minutes. The reaction

- 37 -

mixture was neutralized with TEA (0.5 mL) and evaporated. The residue was purified by chromatography using  $\text{CHCl}_3$ -MeOH 40 mL : 20 drops as the mobile phase to give 2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylamino]-ethyl 2-azido-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-3-O-pentamethylbenzyl- $\beta$ -D-glucopyranoside (37) (220 mg, 77%).

2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylamino]-ethyl 2-amino-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-3-O-pentamethylbenzyl- $\alpha$ , $\beta$ -D-glucopyranoside (38)

A mixture of 2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylamino]-ethyl 2-azido-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-3-O-pentamethylbenzyl- $\beta$ -D-glucopyranoside (37) (160 mg, 0.2 mmol) and TEA (3 drops) in 1,3-propanedithiol (1 mL) was stirred at room temperature overnight. The reaction mixture was chromatographed using EtOAc - hexane 1:1 then EtOAc - MeOH 10:1 solvent systems as mobile phases to give 2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylamino]-ethyl 2-amino-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-3-O-pentamethylbenzyl- $\alpha$ , $\beta$ -D-glucopyranoside (38) (123 mg, 80%)


2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylamino]-ethyl 2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylamino]-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-3-O-pentamethylbenzyl- $\alpha$ , $\beta$ -D-glucopyranoside (39)

A mixture of 2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylamino]-ethyl 2-amino-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-3-O-pentamethylbenzyl- $\beta$ -D-glucopyranoside (38) (50 mg, 0.066 mmol), 1,3-dimethyl-5-[(dimethylamino)methylene]2,4,6(1H,3H,5H)-trioxopyrimidine (Wow-reagent) (50 mg, 0.24 mmol), TEA (0.2 mL) in  $\text{CHCl}_3$  - MeOH 3:1 (4 mL) was stirred at room

- 38 -

temperature for 3 hours. The reaction mixture was evaporated, the resulting residue was chromatographed using EtOAc as the mobile phase to give 2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-ethyl 2-[(1,3-dimethyl-2,4,6(1H,3H,5H)-trioxypyrimidin-5-ylidene)methylamino]-4-O-benzyl-6-O-(4-chlorobenzyl)-2-deoxy-3-O-pentamethylbenzyl- $\alpha,\beta$ -D glucopyranoside (**39**) (45 mg, 75%).

- 10 **Example 8** Selective deprotection study using an Orthogonally Protected Thioglycoside Building Block, Methyl 2-azido-6-O-tert-butylidiphenylsilyl-4-O-biphenylcarbonyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D glucopyranoside (**11**)



**Methyl 2-azido-6-O-tert-butylidiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D glucopyranoside (10)**

- 20 Sodium (89 mg) was reacted in dry MeOH (50 mL) then a solution of methyl 2-azido-4-O-biphenylcarbonyl-6-O-tert-butylidiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D

- 39 -

glucopyranoside (**11**) (3 g, 3.88 mmol) in THF (25 mL) was added. The reaction mixture was stirred at 40 C° for 30 minutes, then cooled to room temperature. The solution was neutralized by Amberlite IR 120 (H<sup>+</sup>) ion exchange resin.

5 The suspension was filtered, the filtrate was evaporated. The residue was purified by chromatography using EtOAc - hexane 1 : 4 as the mobile phase to give methyl 2-azido-6-O-tert-butylidiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio-β-D-glucopyranoside (**10**) (2.1 g, 91%).

10

**Methyl 2-azido-4-O-biphenylcarbonyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio-β-D-glucopyranoside (40)**

To a mixture of methyl 2-azido-4-O-biphenylcarbonyl-6-O-tert-butylidiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio-β-D-glucopyranoside (**11**) (150 mg, 0.19 mmol) and  
15 anhydrous AcOH (2.8 mL) in dry THF (17 mL) hydrogenfluoride-pyridine complex (2 mL) was added in a polypropylene container. The reaction mixture was kept at room temperature overnight, then diluted with EtOAc (100  
20 mL). The resulting solution was washed with saturated sodiumhydrogen carbonate (4 x 100 mL), saturated brine solution (100 mL), dried over MgSO<sub>4</sub> and evaporated to dryness. The residue was purified by chromatography using EtOAc - hexane 2:5 as the mobile phase to give methyl 2-  
25 azido-4-O-biphenylcarbonyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio-β-D-glucopyranoside (**40**) (96 mg, 93%).

**Methyl 2-azido-4-O-biphenylcarbonyl-6-O-tert-butylidiphenylsilyl-2-deoxy-1-thio-β-D-glucopyranoside (41)**

30 A mixture of methyl 2-azido-4-O-biphenylcarbonyl-6-O-tert-butylidiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio-β-D-glucopyranoside (**11**) (150 mg, 0.19 mmol) and DDQ (52 mg, 0.23 mmol) in CH<sub>2</sub>Cl<sub>2</sub> - H<sub>2</sub>O 9:1 (5 mL) was stirred at room temperature for 3 hours. The reaction mixture was washed  
35 with saturated NaHCO<sub>3</sub> solution (3 x 3 ml), dried over MgSO<sub>4</sub> and evaporated. The residue was purified by chromatography using EtOAc - hexane 15:85 as the mobile phase to give

- 40 -

methyl 2-azido-4-O-biphenylcarbonyl-6-O-tert-butylidiphenylsilyl-2-deoxy-1-thio- $\beta$ -D-glucopyranoside (**41**) (116 mg, 92%).

5 **Methyl 2-amino-4-O-biphenylcarbonyl-6-O-tert-butylidiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**42**)**

A mixture of methyl 2-azido-4-O-biphenylcarbonyl-6-O-tert-butylidiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -  
10 D-glucopyranoside (**11**) (150 mg, 0.19 mmol) and TEA (3 drops) in 1,3-propanedithiol (1 mL) was stirred at room temperature overnight. The reaction mixture was chromatographed using EtOAc - hexane 15:85 then EtOAc - hexane 1:1 solvent systems as mobile phases to give methyl  
15 2-amino-4-O-biphenylcarbonyl-6-O-tert-butylidiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**42**) (130 mg, 91%).

20 **3,4-Methylenedioxybenzyl 2-azido-4-O-biphenylcarbonyl-6-O-tert-butylidiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)- $\alpha,\beta$ -D-glucopyranoside (**43**)**

A mixture of methyl 2-azido-4-O-biphenylcarbonyl-6-O-tert-butylidiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)-1-thio- $\beta$ -D-glucopyranoside (**11**) (200 mg, 0.26 mmol), 3,4-methylenedioxybenzyl alcohol 59 mg, 0.39 mmol), molecular  
25 sieves 4A (1 g) and methyltriflate (106 mg, 0.65 mmol) in 1,2-dichloroethane (10 mL) was stirred at room temperature overnight. The reaction mixture was neutralized with TEA (0.5 mL) and evaporated. The residue was purified by  
30 chromatography using EtOAc - hexane 15:85 as the mobile phase to give 3,4-methylenedioxybenzyl 2-azido-4-O-biphenylcarbonyl-6-O-tert-butylidiphenylsilyl-2-deoxy-3-O-(4-methoxybenzyl)- $\alpha,\beta$ -D-glucopyranoside (**43**) (173 mg, 76%).

35 It will be apparent to the person skilled in the art that while the invention has been described in some detail for the purposes of clarity and understanding,

- 41 -

various modifications and alterations to the embodiments and methods described herein may be made without departing from the scope of the inventive concept disclosed in this specification.

5

References cited herein are listed below, and are incorporated herein by this reference.

PCT/AU00/00025

- 42 -

REFERENCES

Merrifield, R. B.

- 5 Pept., Proc. Am. Pept. Symp., 5<sup>th</sup>, 1977 488.

Wong, C-H, Ye, X-S and Zhang, Z.

J. Am. Chem. Soc., 1998 120 7137-7138.


- 10 Wunberg, T., Kallus, C., Opatz, T., Henke, S., Schmidt, W.,  
and Kunz, H.

Angew. Chem. Int. Ed., 1998 37 2503-2505

15

CLAIMS

1. A universal monosaccharide building block of General Formula I or General Formula II



in which

A is a leaving group;

X is hydrogen, O, N or N<sub>3</sub>;

X<sub>1</sub> is hydrogen, -CH<sub>2</sub>O-, -CH<sub>2</sub>NH-, -CH<sub>3</sub>, -CH<sub>2</sub>N<sub>3</sub> or -COO-; and

B, C, D and E are protecting groups which can be cleaved orthogonally,


and in which

B, C, D and E are absent when X is hydrogen or N<sub>3</sub>, and E is absent when X<sub>1</sub> is hydrogen, CH<sub>3</sub> or N<sub>3</sub>.

2. A monosaccharide building block according to claim 1, in which A is selected from the group consisting of -SR; where R is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, halogen; trichloroacetimidoyl-; sulphoxide; and -O-alkenyl.

3. A monosaccharide building block according to claim 1 or claim 2, which is a compound of General Formula III

- 44 -




III

in which

B<sub>1</sub>, C<sub>1</sub>, D<sub>1</sub> and E<sub>1</sub> are orthogonal carbohydrate  
 5 protecting groups selected from protecting group sets 1, 2,  
 6 and 8 as herein defined.

4. A monosaccharide building block according to  
 claim 1 or claim 2, which is a compound of General Formula  
 10 IV



IV


15 in which

B<sub>2</sub>, C<sub>2</sub>, D<sub>2</sub> and E<sub>2</sub> are selected from the members of  
 protecting group set 1, and in themselves constitute an  
 orthogonal set.

20 5. A monosaccharide building block according to  
 claim 4, in which the members of protecting group set 1 are  
 levanoyl, chloroacetate, *p*-methoxybenzyloxycarbonyl and 2-  
 trimethylsilylethylcarbonate.

25 6. A monosaccharide building block according to  
 claim 1 or claim 2, which is a compound of General Formula  
 V

- 45 -



in which

A, X and  $X_1$  are as defined for General Formula I  
 5 and II, and

$B_3$ ,  $C_3$ ,  $D_3$  and  $E_3$  are an orthogonal set of  
 protecting groups selected from amongst the members of set  
 1 and from the remaining orthogonal sets.

10 7. A method of synthesis of a molecule selected from  
 the group consisting of glycoconjugates of non-carbohydrate  
 molecules, neo-glycoconjugates and oligosaccharides,  
 comprising the step of using a monosaccharide building  
 block according to any one of claims 1 to 6.

15 8. A method according to claim 7, in which the  
 molecule comprises one or more compounds in which  
 substituents are linked to a pyranose or furanose ring.

20 9. A method according to claim 7 or claim 8, in  
 which the molecule comprises a sugar analogue.

10. A method according to any one of claims 7 to 9,  
 in which the synthesis is carried out in solution.

25 11. A method according to any one of claims 7 to 9,  
 in which the synthesis is carried out on a solid-phase  
 support.

30

As a below named joint inventor, each of us hereby declares as follows:

My residence, post office address and citizenship are as stated below next to my name.

I believe that I am an original, first, and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**PROTECTING GROUPS FOR CARBOHYDRATE SYNTHESIS**

The specification of which was filed in the U.S. Patent and Trademark Office on 18 July 2001 and assigned application serial No. 09/889,687.

We hereby claim the benefit under 35 U.S.C. § 365 (c) of any PCT international application designating the US, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, we acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the PCT international filing date of this application:

PCT international application number: PCT/AU00/00025, filed July 18, 2000.

We hereby claim foreign priority benefits under 35 U.S.C. §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Australian Patent Application No. PP8230, filed January 18, 1999

I acknowledge the duty to disclose information of which I am aware that is material to the examination of this application in accordance with 37 C.F.R. §1.56(a). That, as to the subject matter of this application, I do not know and do not believe: that this invention was ever known or used in the United States of America before my invention thereof; that this invention was patented or described in any printed publication in any country before my invention thereof or more than one year prior to said application; that this invention was in public use or on sale in the United States of America more than one year prior to said application; that this invention has been patented or made the subject of an inventor's certificate issued before the date of said application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to said application; nor that any application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to said application by me or my legal

representatives or assigns, except for PCT international patent application No. PCT/AU00/00025, filed July 18, 2000 or Australian Patent Application No. PP8230, filed January 18, 1999.

We hereby appoint the following attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith:

12  
**WILLIAM B. ANDERSON, Reg. No. 41,585**

**Y. PING CHOW, Reg. No. 30,740**

**JAMES ALLAN FOX, Reg. No. 38,455**

**DEREK P. FREYBERG, Reg. No. 29,250**

**MARINA HEUSCH, Reg. No. 47,647**

**ROSEMARIE JONES, Reg. No. 46,253**

**WALTER KURZ, Reg. No. 37,373**

**EDWARD J. LYNCH, Reg. No. 24,422**

**PRISCILLA MARK, Reg. No. 41,970**

**WILLIAM SCHMONSEES, Reg. No. 31,796**

**SOODABEH TRONSON, Reg. No. 41,354**

**HERWIG von MORZE, Reg. No. 29,484**

**Heller Ehrman White & McAuliffe LLP**

**275 Middlefield Road**

**Menlo Park, CA 94025-3506**

**Phone: (650) 324-7000**

**Fax: (650) 324-0638**

**Please address correspondence in this matter to:**

**William Schmonsees**

**Phone: (650) 324-7041**

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

100 **FIRST NAMED INVENTOR**

**INVENTOR'S SIGNATURE**

**DATE**

Gyula Dekany

*x Gyula Dekany*

*14/9/2001*

## DECLARATION AND POWER OF ATTORNEY

Attorney Docket No. 26979-0002

RESIDENCE  
West Lake, Australia

CITIZENSHIP  
Hungary

POST OFFICE ADDRESS  
51 Tekapo Street  
WEST LAKE, Queensland 4074  
Australia

**SECOND NAMED INVENTOR****INVENTOR'S SIGNATURE****DATE**

John Papageorgiou

RESIDENCE  
~~Indooroopilly~~, Australia

Salisbury East


CITIZENSHIP  
Australia

POST OFFICE ADDRESS  
Unit 6  
101 Harris Road  
~~INDOOROOPIILLY~~, Queensland 4068  
Australia

25 Farmer Street  
Salisbury East  
South Australia  
Australia 5109

**THIRD NAMED INVENTOR****INVENTOR'S SIGNATURE****DATE**

Laurent Francois Bornaghi



21.09.2001

RESIDENCE  
Forest Lake, Australia *AU*

CITIZENSHIP  
France

POST OFFICE ADDRESS  
16 Flinders Street  
FOREST LAKE, Queensland 4078  
Australia

311065 v01 SV (5 0P01! DOC)  
7/20/01 4:35 PM (26979 0002)

## DECLARATION AND POWER OF ATTORNEY

Attorney Docket No. 26979-0002

## RESIDENCE

West Lake, Australia *AUX*

## CITIZENSHIP

Hungary

## POST OFFICE ADDRESS

51 Tekapo Street  
WEST LAKE, Queensland 4074  
Australia

2-00  
SECOND NAMED INVENTORJohn Papageorgiou

## INVENTOR'S SIGNATURE

X 

## DATE

*17/9/01*

## RESIDENCE

~~Indooroopilly~~, Australia *AUX*

## CITIZENSHIP

Australia

Salisbury East

## POST OFFICE ADDRESS

~~Unit 6~~  
~~101 Harris Road~~  
~~INDOOROOPILLY, Queensland 4068~~  
~~Australia~~

25 Farmer Street  
Salisbury East  
South Australia  
Australia 5109

## THIRD NAMED INVENTOR

Laurent Francois Bornaghi

## INVENTOR'S SIGNATURE

## DATE

## RESIDENCE

Forest Lake, Australia

## CITIZENSHIP

France

## POST OFFICE ADDRESS

16 Flinders Street  
FOREST LAKE, Queensland 4078  
Australia

311065 v01 SV (6\_0P011.DOC)  
7/20/01 4 35 PM (26979 0002)